According to a recent LinkedIn post from M Ventures, portfolio company STORM Therapeutics has reportedly closed a $56 million Series C financing round. The post suggests that the funding is intended to advance STORM’s RNA-modification platform focused on cancer therapies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that capital will be used to accelerate development of STC-15, described as a first-in-class, oral small-molecule METTL3 inhibitor. It also notes that the first patient has been dosed in a Phase 2 monotherapy study in selected sarcoma indications, signaling progression into mid-stage clinical testing.
From an investor perspective, the financing implies continued backing for STORM’s oncology pipeline, potentially extending its cash runway and supporting value-inflection milestones. Progress into Phase 2 could, if results are positive, position the asset for an expedited regulatory pathway in sarcoma and create optionality for broader oncology indications.
For M Ventures, participation in a sizable late private round within a specialized oncology niche may reflect a continued focus on high-science, high-risk therapeutics with significant upside potential. Successful clinical advancement or eventual partnering of STC-15 could enhance portfolio returns, while clinical or regulatory setbacks would represent a key downside risk to the implied value of this investment exposure.